Calcitonin gene-related peptide explained

Calcitonin-related polypeptide alpha
Caption:Human calcitonin (black) bound to the calcitonin receptor.
Width:173
Hgncid:1437
Symbol:CALCA
Altsymbols:CALC1
Entrezgene:796
Omim:114130
Refseq:NM_001741
Uniprot:P06881
Chromosome:11
Arm:p
Band:15.2
Calcitonin-related polypeptide, beta
Hgncid:1438
Symbol:CALCB
Altsymbols:CALC2
Entrezgene:797
Omim:114160
Refseq:NM_000728
Uniprot:P10092
Chromosome:11
Arm:p
Band:15.2

Calcitonin gene-related peptide (CGRP) is a neuropeptide that belongs to the calcitonin family.[1] Human CGRP consists of two isoforms, CGRP alpha (α-CGRP, also known as CGRP I) and CGRP beta (β-CGRP, also known as CGRP II).[2] α-CGRP is a 37-amino acid neuropeptide formed by alternative splicing[3] of the calcitonin/CGRP gene located on chromosome 11. β-CGRP is less studied. In humans, β-CGRP differs from α-CGRP by three amino acids and is encoded in a separate, nearby gene.[4] The CGRP family includes calcitonin (CT), adrenomedullin (AM), and amylin (AMY).[5]

Function

CGRP is produced in both peripheral and central neurons.[6] It is a potent peptide vasodilator and can function in the transmission of nociception.[7] [8] In the spinal cord, the function and expression of CGRP may differ depending on the location of synthesis. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and may contribute to the regeneration of nervous tissue after injury. Conversely, CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and may be linked to the transmission of pain.[9] In the trigeminal vascular system, the cell bodies of the trigeminal ganglion are the main source of CGRP. CGRP is thought to play a role in cardiovascular homeostasis and nociception. In the heart, CGRP acts as a chronotrope by increasing heart rate.[10] Apart from these attributes, CGRP is known to modulate the autonomic nervous system and plays a role in ingestion.

CGRP has moderate effects on calcium homeostasis compared to its extensive actions in other areas, such as the autonomic nervous system.

Functions

As a neuropeptide, CGRP acts as an appetite suppressant and contributes to gastric acid secretion. It also functions in temperature homeostasis, increases heart rate, and plays a role in the release of the pituitary hormones in a paracrine manner. Because of these characteristics, it has been said that CGRP functions more as a neurotransmitter than a hormone.

Stem cell mobilization

CGRP has a role in human stem cell (HSC) mobilization.[11] In investigations carried out in 2021, treatment with CGRP resulted in significantly increased CGRP levels in the bone marrow extracellular fluid and substantially increased the number of HSCs mobilized by granulocyte colony-stimulating factor (G-CSF).[12] The authors of the 2021 study concluded that G-CSF-induced HSC mobilization is regulated by the nociceptor nerve-derived neuropeptide CGRP. This peptide exerts its effect on HSC mobilization via the receptor activity-modifying protein 1 (RAMP1) pathway.

Receptors

CGRP mediates its effects through a heteromeric receptor composed of a G protein-coupled receptor called calcitonin receptor-like receptor (CALCRL) and RAMP1.[13] CGRP receptors are found throughout all the body, suggesting that the protein may modulate a variety of physiological functions in all major systems (e.g., respiratory, endocrine, gastrointestinal, immune, and cardiovascular).[14] These transmembrane receptors form folded accordion-like structures embedded in the cell membrane with loops of protein on the inside (intracellular loops) and outside (extracellular loops) of the membrane. The second extracellular loop is fundamental for ligand-induced activation, with key interactions of R274/Y278/D280/W283.[15]

Regulation

Regulation of the CGRP gene is in part controlled by the expression of the mitogen-activated protein kinase (MAPK) signaling pathway and cytokines like TNFα and iNOS.[16] [17] [18] 5HT1 receptor agonists like sumatriptan increase intracellular calcium, which causes decreases in CGRP promoter activity.

CGRP receptors are found in myelinated A-fiber axons which is required for ligand specificity and function of the receptor. The CGRP receptor has three subunits: receptor activity-modifying protein 1 (RAMP1), calcitonin-like receptor (CLR) and receptor component protein (RCP).[19] The complex central receptor is the G protein-coupled receptor calcitonin receptor-like receptor (CALCRL) which is necessary for CGRP and adrenomedullin (AM receptors). For function CGRP, CALCRL must coincide with RAMP1 where the ligand-binding domain of CGRP is located. It also includes two cytoplasmic proteins that associate with the CALCRL-RAMP1 to form signal transduction. CALCRL contains the Gα subunit, which activates adenylyl cyclase and cAMP-dependent signaling pathways. Receptor-mediated transduction elevates in intracellular cAMP activate protein kinase A, which results in the phosphorylation of multiple targets, including potassium- sensitive ATP channels (KATP channels), extracellular signal-related kinases and transcription factors such as cAMP-responsive element-binding protein (CREB). In smooth muscle of neurovascular region, the elevation of cAMP upon CGRP activation results in vasodilation of the blood vessel. Chronic exposure to CGRP causes degradation of lysosomes.[20]

Research

Increased levels of CGRP have been reported in migraine and temporomandibular joint disorder patients as well as a variety of other diseases such as cardiac failure, hypertension, and sepsis.[21] [22] [23] [24] [25] [26] [27]

There is mounting evidence to suggest that CGRP may be beneficial in preventing the development of hypertension and cardiovascular pathologies associated with hypertension. This is of particular concern, as females (16.6%) are more genetically predisposed to migraine than are males (7.5%).[28]

Preclinical evidence suggests that, during a migraine, activated primary sensory neurons (meningeal nociceptors) in the trigeminal ganglion release CGRP from their peripherally projecting nerve endings located within the meninges.[29] This CGRP then binds to and activates CGRP receptors located around meningeal vessels, causing vasodilation, mast cell degranulation, and plasma extravasation.[30] [31] Human observations have further implicated the role of CGRP in the pathophysiology of migraine. Activation of primary sensory neurons in the trigeminal vascular system in humans can cause the release of CGRP. During some migraine attacks, increased concentrations of CGRP can be found in both saliva and in plasma drawn from the external jugular vein. Furthermore, intravenous administration of alpha-CGRP is able to induce headache in individuals susceptible to migraine.[32]

Medicines

Treatments based on monoclonal antibodies have been produced related to CGRP or CGRP receptors. They have been shown to be effective in patients who experience migraine headaches, both with and without aura, and both episodic and chronic cluster headache. These are the first class of preventive medications originally designed and approved for people with migraine. While these medications are often considered to have no or few side effects, a growing number of patients have reported severe, ongoing side effects including disabling lower back pain, muscle pain, neuropathy, and more. Due to the nature of the monoclonal antibodies, they must be administered parenterally, preferably by injection.[33]

The first CGRP related medication approved by the FDA is called erenumab (trade name Aimovig), produced by pharmaceutical company Amgen and Novartis. It interacts with the CGRP receptor. It is injected once monthly with a dose of 70 or 140 mg. Few adverse effects were reported (most related to injection site reactions) and patients had a significant reduction in migraines.[34] [35]

The second approved by the FDA is called fremanezumab (trade name Ajovy), produced by the Teva Pharmaceuticals company. It interacts with the CGRP protein, whose expression is related to migraine attacks. It may be administered monthly or every three months, giving options for users. Trials have shown a reduction of greater than 50% of migraine days for those who responded. There were few significant side effects during trials, most related to injection site reactions.[36] [37]

The third approved by the FDA is called galcanezumab (trade name Emgality), produced by the Eli Lilly and Company. It interacts with the CGRP protein, whose expression is related to migraine attacks. It is injected once a month, after the first month having a double dose. The main reported side effects are injection site reactions, although there are a growing number of reports of severe side effects from a minority of patients.[38] [39]

Approved by the FDA in February 2020, ubrogepant (Ubrelvy) is an oral medication manufactured by AbbVie.

Also FDA approved in February 2020, eptinezumab (Vyepti), is an intravenous migraine prophylactic medication manufactured by Lundbeck.

Rimegepant (Nurtec ODT) subsequently became the first oral CGRP receptor antagonist to be approved by the FDA for both acute migraine treatment (approved February 2020) and prevention of episodic migraine (approved June 2021).[40] It is manufactured by Pfizer.

In September 2021 the FDA approved Qulipta (atogepant), the first oral CGRP receptor antagonist approved to prevent chronic migraine.[41]

The phytocannabinoids delta-9 tetrahydrocannabinol (Δ9-THC) and its oxidative byproduct cannabinol (CBN) are found to induce a CB1 and CB2 cannabinoid receptor-independent release of calcitonin gene-related peptide from capsaicin-sensitive perivascular sensory nerves, an action that other psychotropic cannabinoids cannot do.[42] [43]

Notes and References

  1. Russell . F. A. . King . R. . Smillie . S.-J. . Kodji . X. . Brain . S. D. . October 2014 . Calcitonin Gene-Related Peptide: Physiology and Pathophysiology . Physiological Reviews . 94 . 4 . 1099–1142 . 10.1152/physrev.00034.2013 . 0031-9333 . 4187032 . 25287861.
  2. Russell FA, King R, Smillie SJ, Kodji X, Brain SD . Calcitonin gene-related peptide: physiology and pathophysiology . Physiological Reviews . 94 . 4 . 1099–142 . October 2014 . 25287861 . 4187032 . 10.1152/physrev.00034.2013 .
  3. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM . Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products . Nature . 298 . 5871 . 240–4 . July 1982 . 6283379 . 10.1038/298240a0 . 24188834 . 1982Natur.298..240A .
  4. Rezaeian AH, Isokane T, Nishibori M, Chiba M, Hiraiwa N, Yoshizawa M, Yasue H . alphaCGRP and betaCGRP transcript amount in mouse tissues of various developmental stages and their tissue expression sites . Brain & Development . 31 . 9 . 682–93 . October 2009 . 19062206 . 10.1016/j.braindev.2008.10.011 . 21635386 .
  5. Edvinsson L . The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine . Headache . 57 Suppl 2 . S2 . 47–55 . May 2017 . 28485848 . 10.1111/head.13081 . free .
  6. Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM . 6 . Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing . Nature . 304 . 5922 . 129–35 . 1983 . 6346105 . 10.1038/304129a0 . 1983Natur.304..129R . 4322278 .
  7. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I . Calcitonin gene-related peptide is a potent vasodilator . Nature . 313 . 5997 . 54–6 . 1985 . 3917554 . 10.1038/313054a0 . 1985Natur.313...54B . 4329128 .
  8. McCulloch J, Uddman R, Kingman TA, Edvinsson L . Calcitonin gene-related peptide: functional role in cerebrovascular regulation . Proceedings of the National Academy of Sciences of the United States of America . 83 . 15 . 5731–5 . August 1986 . 3488550 . 386363 . 10.1073/pnas.83.15.5731 . 1986PNAS...83.5731M . free .
  9. Chen LJ, Zhang FG, Li J, Song HX, Zhou LB, Yao BC, Li F, Li WC . 6 . Expression of calcitonin gene-related peptide in anterior and posterior horns of the spinal cord after brachial plexus injury . Journal of Clinical Neuroscience . 17 . 1 . 87–91 . January 2010 . 19969463 . 10.1016/j.jocn.2009.03.042 . 29249307 .
  10. Book: Hormones . Norman A, Henry H, Litwack G . Elsevier . 2014 . 978-0-12-369444-7. Amsterdam .
  11. Chen. Qingquan. Zhang. Shuyu. Gao. Feng. Liu. Qicai. 2022-01-29 . CGRP: A New Endogenous Cell Stemness Maintenance Molecule . Oxidative Medicine and Cellular Longevity . 2022 . 4107433 . 10.1155/2022/4107433 . free. 1942-0900 . 8817839 . 35132349. Lv. Xiaoting.
  12. Gao X, Zhang D, Xu C, Li H, Caron KM, Frenette PS . Nociceptive nerves regulate haematopoietic stem cell mobilization . Nature . 589 . 7843 . 591–596 . January 2021 . 33361809 . 7856173 . 10.1038/s41586-020-03057-y . 2021Natur.589..591G .
  13. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM . 17302944 . 6 . International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors . Pharmacological Reviews . 54 . 2 . 233–46 . June 2002 . 12037140 . 10.1124/pr.54.2.233 .
  14. Arulmani U, Maassenvandenbrink A, Villalón CM, Saxena PR . Calcitonin gene-related peptide and its role in migraine pathophysiology . European Journal of Pharmacology . 500 . 1–3 . 315–30 . October 2004 . 15464043 . 10.1016/j.ejphar.2004.07.035 .
  15. Woolley MJ, Simms J, Mobarec JC, Reynolds CA, Poyner DR, Conner AC . Understanding the molecular functions of the second extracellular loop (ECL2) of the calcitonin gene-related peptide (CGRP) receptor using a comprehensive mutagenesis approach . Molecular and Cellular Endocrinology . 454 . 39–49 . October 2017 . 28572046 . 10.1016/j.mce.2017.05.034 . 13779528 .
  16. Durham PL, Russo AF . Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons . The Journal of Neuroscience . 23 . 3 . 807–15 . February 2003 . 12574409 . 6741928 . 10.1523/JNEUROSCI.23-03-00807.2003 .
  17. Schäfers M, Svensson CI, Sommer C, Sorkin LS . Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons . The Journal of Neuroscience . 23 . 7 . 2517–21 . April 2003 . 12684435 . 6742090 . 10.1523/JNEUROSCI.23-07-02517.2003 .
  18. Li J, Vause CV, Durham PL . Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells . Brain Research . 1196 . 22–32 . February 2008 . 18221935 . 2268710 . 10.1016/j.brainres.2007.12.028 .
  19. Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, Vigneri S, Edvinsson L, Maassen Van Den Brink A . 6 . Blocking CGRP in migraine patients - a review of pros and cons . . 18 . 1 . 96 . September 2017 . 28948500 . 5612904 . 10.1186/s10194-017-0807-1 . free .
  20. Edvinsson L, Haanes KA, Warfvinge K, Krause DN . CGRP as the target of new migraine therapies - successful translation from bench to clinic . Nature Reviews. Neurology . 14 . 6 . 338–350 . June 2018 . 29691490 . 10.1038/s41582-018-0003-1 . 13810025 .
  21. Buzzi MG, Bonamini M, Moskowitz MA . Neurogenic model of migraine . Cephalalgia . 15 . 4 . 277–80 . 1995 . 7585923 . 10.1046/j.1468-2982.1995.1504277.x . 1403941 .
  22. Goto K, Miyauchi T, Homma S, Ohshima N . Calcitonin gene-related peptide in the regulation of cardiac function . Annals of the New York Academy of Sciences . 657 . 1 . 194–203 . June 1992 . 1637085 . 10.1111/j.1749-6632.1992.tb22768.x . 1992NYASA.657..194G . 43409084 .
  23. Joyce CD, Fiscus RR, Wang X, Dries DJ, Morris RC, Prinz RA . Calcitonin gene-related peptide levels are elevated in patients with sepsis . Surgery . 108 . 6 . 1097–101 . December 1990 . 2247835 .
  24. Edvinsson L, Goadsby PJ . Neuropeptides in migraine and cluster headache . Cephalalgia . 14 . 5 . 320–7 . October 1994 . 7828188 . 10.1046/j.1468-2982.1994.1405320.x . 29949980 .
  25. Ferrari MD, Saxena PR . On serotonin and migraine: a clinical and pharmacological review . Cephalalgia . 13 . 3 . 151–65 . June 1993 . 8395342 . 10.1046/j.1468-2982.1993.1303151.x . 23099581 .
  26. Goadsby PJ, Edvinsson L . Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies . Brain . 117 (Pt 3) . 3 . 427–34 . June 1994 . 7518321 . 10.1093/brain/117.3.427 .
  27. Web site: What to Know About the New CGRP Migraine Treatment Options . 23 February 2019 . American Migraine Foundation . Tepper S.
  28. Pellesi L, Guerzoni S, Pini LA . Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date . Clinical Pharmacology in Drug Development . 6 . 6 . 534–547 . November 2017 . 28409893 . 5697612 . 10.1002/cpdd.345 .
  29. Durham PL . Calcitonin gene-related peptide (CGRP) and migraine . Headache . 46 . Suppl 1 . S3-8 . June 2006 . 16927957 . 3134175 . 10.1111/j.1526-4610.2006.00483.x .
  30. Goadsby PJ, Edvinsson L, Ekman R . Vasoactive peptide release in the extracerebral circulation of humans during migraine headache . Annals of Neurology . 28 . 2 . 183–7 . August 1990 . 1699472 . 10.1002/ana.410280213 . 12568270 .
  31. Edvinsson L . Neuronal signal substances as biomarkers of migraine . Headache . 46 . 7 . 1088–94 . 2006 . 16866713 . 10.1111/j.1526-4610.2006.00502.x . 24433430 .
  32. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J . CGRP may play a causative role in migraine . Cephalalgia . 22 . 1 . 54–61 . February 2002 . 11993614 . 10.1046/j.1468-2982.2002.00310.x . 24779840 . free .
  33. Wang W, Wang EQ, Balthasar JP . November 2008 . Monoclonal antibody pharmacokinetics and pharmacodynamics . Clinical Pharmacology and Therapeutics . 84 . 5 . 548–58 . 10.1038/clpt.2008.170 . 18784655 . 7994962.
  34. Web site: Rosenberg J . FDA Approves Erenumab, First CGRP Inhibitor for Prevention of Migraine . AJMC.com . 18 May 2018 . 23 February 2019 .
  35. Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M . 67790108 . Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety . Drugs . 79 . 4 . 417–431 . March 2019 . 30793254 . 10.1007/s40265-019-01069-1 .
  36. Web site: FDA Approves Second Anti-CGRP Treatment for Migraines . American Migraine Foundation . 23 February 2019 .
  37. Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E . 52962394 . From LBR-101 to Fremanezumab for Migraine . CNS Drugs . 32 . 11 . 1025–1037 . November 2018 . 30311143 . 10.1007/s40263-018-0579-4 .
  38. Web site: Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults . Lilly . 23 February 2019 .
  39. Lamb YN . 53107438 . Galcanezumab: First Global Approval . Drugs . 78 . 16 . 1769–1775 . November 2018 . 30378008 . 10.1007/s40265-018-1002-7 .
  40. Web site: 2025-07-09 . Nurtec (Rimegepant) becomes first migraine therapy for acute and preventive treatment . 2025-07-09 . CGRP Forum.
  41. Web site: FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine . Drugs.com . 19 September 2024 .
  42. Web site: Degradants Formed During Phytocannabinoid Processing . 2023-05-10 . www.caymanchem.com . en.
  43. Zygmunt PM, Andersson DA, Hogestatt ED . Δ9-Tetrahydrocannabinol and Cannabinol Activate Capsaicin-Sensitive Sensory Nerves via a CB1 and CB2 Cannabinoid Receptor-Independent Mechanism . The Journal of Neuroscience . 22 . 11 . 4720–7 . June 2002 . 12040079 . 6758782 . 10.1523/JNEUROSCI.22-11-04720.2002.